Table 3. omparison of Barthel Index scores between the five groups and placebo pre- and post-therapy.
| Groups | n | Pretherapy | Post-therapy | |||
|---|---|---|---|---|---|---|
| Day 11 | 90 days | |||||
| Abbreviations: ANOVA, analysis of variance; SD, standard deviation. Note: Values are expressed as mean ± SD. | ||||||
| 1 p < 0.001 versus the placebo group by ANOVA. | ||||||
| 2 p < 0.001 versus the placebo group by ANOVA. | ||||||
| 3 p = 0.07 versus the placebo group by ANOVA. | ||||||
| 4 p = 0.03 versus the placebo group by ANOVA. | ||||||
| a p < 0.001 versus the placebo group by ANOVA. | ||||||
| b p < 0.001 versus the placebo group by ANOVA. | ||||||
| c p = 0.06 versus the placebo group by ANOVA. | ||||||
| d p = 0.02 versus the placebo group by ANOVA. | ||||||
| * p -value significant. | ||||||
| Citicoline | 20 | 36.0 ± 17.13 | 64.0 ± 17.13 1 , * | 86.0 ± 8.19 a , * | ||
| Edaravone | 20 | 37.5 ± 19.0 | 68.68 ± 12.75 2 , * | 88.88 ± 6.18 b , * | ||
| Minocycline | 20 | 31.0 ± 17.59 | 51.5 ± 20.20 3 | 76.35 ± 8.12 c | ||
| Cerebrolysin | 20 | 35.0 ± 20.19 | 57.25 ± 21.61 4 , * | 78.33 ± 12.83 d , * | ||
| Placebo | 20 | 38.0 ± 17.95 | 54.25 ± 21.10 | 74.82 ± 10.83 | ||